Market Overview

7 Biggest Price Target Changes For Thursday

Share:
  • JP Morgan boosted the price target for Abercrombie & Fitch Co. (NYSE: ANF) from $19 to $27. Abercrombie & Fitch shares closed at $25.70 on Wednesday.
  • JP Morgan raised the price target on Estee Lauder Companies Inc (NYSE: EL) from $160 to $175. Estee Lauder shares closed at $153.88 on Wednesday.
  • KeyBanc Capital lifted the price target for Paypal Holdings Inc (NASDAQ: PYPL) from $105 to $110. Paypal shares closed at $96.46 on Wednesday.
  • Credit Suisse raised the price target for Dollar Tree, Inc. (NASDAQ: DLTR) from $105 to $110. Dollar Tree shares closed at $100.35 on Wednesday.
  • Oppenheimer raised Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) price target from $200 to $230. Vertex Pharmaceuticals shares closed at $181.11 on Wednesday.
  • Stifel Nicolaus lowered the price target for Allergan plc (NYSE: AGN) from $195 to $175. Allergan shares closed at $137.51 on Wednesday.
  • Wedbush cut the price target for Idera Pharmaceuticals Inc (NASDAQ: IDRA) from $16 to $7. Idera Pharmaceuticals shares closed at $2.62 on Wednesday.

Posted-In: Price Target ChangesPrice Target Intraday Update Analyst Ratings

 

Related Articles (AGN + ANF)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Why Banning 'Marijuana' From The Cannabis Industry Doesn't Work

Facebook's Zuckerberg Presents 'Privacy-Focused Vision'